REGN Regeneron Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REGN

Price (delayed)

$759.25

Market cap

$83.01B

P/E Ratio

18.74

Dividend/share

N/A

EPS

$40.51

Enterprise value

$82.6B

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights
The equity has grown by 21% year-on-year and by 6% since the previous quarter
The gross margin has grown by 2.8% YoY and by 2.1% from the previous quarter
The quick ratio has grown by 40% YoY but it has contracted by 4.8% from the previous quarter
The company's EPS fell by 47% YoY and by 19% QoQ
Regeneron Pharmaceuticals's net income has decreased by 46% YoY and by 19% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.regeneron.com/
Peers: AMGN ALNY BIIB JNJ

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
109.33M
Market cap
$83.01B
Enterprise value
$82.6B
Valuations
Price to earnings (P/E)
18.74
Price to book (P/B)
3.65
Price to sales (P/S)
6.68
EV/EBIT
16.79
EV/EBITDA
15.7
EV/Sales
6.79
Earnings
Revenue
$12.17B
EBIT
$4.92B
EBITDA
$5.26B
Free cash flow
$4.42B
Per share
EPS
$40.51
Free cash flow per share
$41.31
Book value per share
$208.11
Revenue per share
$113.66
TBVPS
$264.23
Balance sheet
Total assets
$29.21B
Total liabilities
$6.55B
Debt
$2.7B
Equity
$22.66B
Working capital
$12.74B
Liquidity
Debt to equity
0.12
Current ratio
5.06
Quick ratio
4.16
Net debt/EBITDA
-0.08
Margins
EBITDA margin
43.2%
Gross margin
87.2%
Net margin
35.6%
Operating margin
38.9%
Efficiency
Return on assets
15.7%
Return on equity
20.5%
Return on invested capital
20.9%
Return on capital employed
18.9%
Return on sales
40.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
1.55%
1 week
0.92%
1 month
1.4%
1 year
10.69%
YTD
5.23%
QTD
5.23%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$12.17B
Gross profit
$10.61B
Operating income
$4.74B
Net income
$4.34B
Gross margin
87.2%
Net margin
35.6%
The operating income fell by 47% YoY and by 24% QoQ
Regeneron Pharmaceuticals's net income has decreased by 46% YoY and by 19% QoQ
Regeneron Pharmaceuticals's operating margin has decreased by 30% YoY and by 15% QoQ
The net margin has decreased by 29% YoY and by 9% from the previous quarter

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
18.74
P/B
3.65
P/S
6.68
EV/EBIT
16.79
EV/EBITDA
15.7
EV/Sales
6.79
The company's EPS fell by 47% YoY and by 19% QoQ
REGN's price to earnings (P/E) is 44% higher than its last 4 quarters average of 13.0 and 14% higher than its 5-year quarterly average of 16.5
The equity has grown by 21% year-on-year and by 6% since the previous quarter
REGN's price to book (P/B) is 17% less than its 5-year quarterly average of 4.4 but 4.3% more than its last 4 quarters average of 3.5
The P/S is 28% higher than the last 4 quarters average of 5.2 and 6% higher than the 5-year quarterly average of 6.3
The revenue has decreased by 24% YoY and by 11% QoQ

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on equity has shrunk by 60% YoY and by 23% QoQ
Regeneron Pharmaceuticals's return on invested capital has shrunk by 58% YoY and by 22% QoQ
The return on assets has dropped by 57% year-on-year and by 22% since the previous quarter
The company's return on sales fell by 31% YoY and by 9% QoQ

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
The current ratio is up by 42% YoY but it is down by 6% QoQ
The quick ratio has grown by 40% YoY but it has contracted by 4.8% from the previous quarter
The debt is 88% less than the equity
The equity has grown by 21% year-on-year and by 6% since the previous quarter
REGN's debt to equity is down by 14% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.